NIDCR's Spring 2021 E-Newsletter
Having trouble viewing this email? View it as a Web page. NIDCR's Spring 2021 E-Newsletter In this issue: NIDCR News Funding Opportunities & Related Notices NIH/HHS News Subscribe to NICDR News Science Advances   Grantee News   NIDCR News NIDCR & NIH Stand Against Structural Racism NIDCR Director Rena D’Souza, DDS, MS, PhD, said in a statement that there is no place for structural racism in biomedical research, echoing remarks from NIH Director Francis Collins, MD, PhD, in his announcement of a new NIH ...
Source: NIDCR Science News - April 7, 2021 Category: Dentistry Source Type: news

LSU Health New Orleans study discovers source of Zika neurodevelopmental defects
(Louisiana State University Health Sciences Center) A study led by Edward Wojcik, PhD, Associate Professor of Biochemistry& Molecular Biology at LSU Health New Orleans School of Medicine, identified how microcephaly (abnormally small heads) and blindness may develop in Zika-infected fetuses, as well as a new way to potentially prevent these neurodevelopmental defects. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - April 6, 2021 Category: Infectious Diseases Source Type: news

Johnson & Johnson Expands Phase 2a Clinical Trial of COVID-19 Vaccine Candidate to Include Adolescents
New Brunswick, NJ (April 2, 2021) – Johnson & Johnson (the Company) has begun vaccinating adolescent participants in the ongoing Phase 2a clinical trial for its COVID-19 vaccine candidate, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson. “The COVID-19 pandemic has had a profound impact on adolescents, not just with the complications of the disease, but with their education, mental health, and wellbeing,” said Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific Officer at Johnson & Johnson. “It is vital that we develop vaccines for eve...
Source: Johnson and Johnson - April 2, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

UConn researcher develops successful Zika vaccine in preclinical studies
(University of Connecticut) Paulo Verardi from UConn's College of Agriculture, Health and Natural Resources has demonstrated the success of a vaccine against Zika virus and recently published his findings in Scientific Reports. The vaccine was generated using Verardi's novel patent-pending platform technology. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - April 1, 2021 Category: Biology Source Type: news

Johnson & Johnson Announces Advance Purchase Agreement with the African Vaccine Acquisition Trust for the Company ’s COVID-19 Vaccine Candidate
NEW BRUNSWICK, NJ (March 29, 2021) - Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ) (the Company), has entered into an agreement with the African Vaccine Acquisition Trust (AVAT) to make available up to 220 million doses of its single-shot COVID-19 vaccine candidate to African Union’s 55 member states with delivery beginning in the third quarter of 2021. AVAT also has the potential to order an additional 180 million doses, for a combined total of up to 400 million doses through 2022. The availability of the vaccine candidate is subject to its successful appr...
Source: Johnson and Johnson - March 29, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Statement on the Interim SAGE Recommendation Supporting the Use of the Johnson & Johnson COVID-19 Vaccine
New Brunswick, NJ (March 17, 2021) – We welcome the interim recommendation by the Strategic Advisory Group of Experts (SAGE) on Immunization for the World Health Organization (WHO) supporting the use of Johnson & Johnson’s single-shot COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson, to prevent COVID-19 in persons aged 18 years and above. SAGE advises WHO on global vaccine and immunization policies and its recommendations for use provide guidance on the use of vaccines supplied through the COVAX Facility, a global risk-sharing mechanism for pooled procurement and ...
Source: Johnson and Johnson - March 17, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Johnson & Johnson Single-Shot COVID-19 Vaccine Granted Emergency Use Listing by the World Health Organization
NEW BRUNSWICK, N.J., March 12, 2021– Johnson & Johnson (NYSE: JNJ) (the Company) today announced that the World Health Organization (WHO) has issued Emergency Use Listing (EUL) for its single-shot COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), to prevent COVID-19 in individuals 18 years of age and older.Data from the Phase 3 ENSEMBLE study showed that the Johnson & Johnson COVID-19 vaccine was well tolerated and demonstrated a 67 percent reduction in symptomatic COVID-19 disease in participants who received the vaccine in comparison to participants give...
Source: Johnson and Johnson - March 12, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Johnson & Johnson Single-Shot COVID-19 Vaccine Granted Conditional Marketing Authorization by European Commission
NEW BRUNSWICK, N.J., March 11, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced that the European Commission (EC) has granted a Conditional Marketing Authorization (CMA) for its single-dose COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), to prevent COVID-19 in individuals 18 years of age and older. The CMA follows a Positive Opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP).2 The CMA is valid in all 27 member states of the European Union (EU), plus Norway, Iceland and Liechtenstei...
Source: Johnson and Johnson - March 11, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Johnson & Johnson Announces its Single-Shot COVID-19 Vaccine Candidate Receives Positive CHMP Opinion
NEW BRUNSWICK, N.J., March 11, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a Positive Opinion to recommend the Conditional Marketing Authorization (CMA) for its single-dose COVID-19 vaccine candidate, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), to prevent COVID-19 in individuals 18 years of age and older. Data from the Phase 3 ENSEMBLE study showed that the Johnson & Johnson COVID-19 vaccine was well tolerated and demonstrated a 67 percen...
Source: Johnson and Johnson - March 11, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Study of mosquito protein could lead to treatments against life-threatening viruses
Protein AEG12 strongly inhibits the family of viruses that cause yellow fever, dengue, West Nile, and Zika. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - March 10, 2021 Category: American Health Source Type: news

Study of mosquito protein could lead to treatments against life-threatening viruses
(NIH/National Institute of Environmental Health Sciences) The mosquito protein AEG12 strongly inhibits the family of viruses that cause yellow fever, dengue, West Nile, and Zika and weakly inhibits coronaviruses, according to scientists at the National Institutes of Health (NIH) and their collaborators. The researchers found that AEG12 works by destabilizing the viral envelope, breaking its protective covering. The findings could lead to therapeutics against viruses that affect millions of people around the world. The research was published online in PNAS. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - March 10, 2021 Category: Infectious Diseases Source Type: news

Johnson & Johnson COVID-19 Vaccine Granted Authorization under Interim Order by Health Canada For Emergency Use
March 5, 2021 - Johnson & Johnson (the Company) announced today that Health Canada has granted an Interim Order (IO) authorization for its single-shot COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson, to prevent COVID-19 in individuals 18 years of age and older.This decision was based on scientific evidence, including data from the Phase 3 ENSEMBLE study that demonstrated the vaccine was 85 percent effective in preventing severe disease, and showed protection against COVID-19 related hospitalization and death, beginning 28 days after vaccination.Johnson & Johnson anticipa...
Source: Johnson and Johnson - March 5, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

NIDCR Science News - March 2021
Having trouble viewing this email? View it as a Web page. A monthly update of NIDCR-supported science advances, as reported by grantee institutions and NIH. A Search for Cell Identity NIDCR's Dr. Roxane Tussiwand studies how immune cells are shaped by their surroundings NIDCR • February 22, 2021 The Scarred Villain: Study Explores Neurocognitive Basis of Bias Against People Who Look DifferentUniversity of Pennsylvania • February 12, 2021 Study Reveals C...
Source: NIDCR Science News - March 2, 2021 Category: Dentistry Source Type: news

Johnson & Johnson Announces U.S. CDC Advisory Committee Recommends First Single-Shot COVID-19 Vaccine for Adults 18 and Older in U.S.
NEW BRUNSWICK, N.J., February 28, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) has recommended the first single-shot COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson, for individuals 18 years of age and older under the Emergency Use Authorization (EUA) issued by the U.S. Food and Drug Administration (FDA). “For more than 130 years, Johnson & Johnson has come to the aid of people during times of crisis, and we believe ...
Source: Johnson and Johnson - February 28, 2021 Category: Pharmaceuticals Source Type: news

Johnson & Johnson COVID-19 Vaccine Authorized by U.S. FDA For Emergency Use
NEW BRUNSWICK, N.J., February 27, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for its single-dose COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson, to prevent COVID-19 in individuals 18 years of age and older. This decision was based on the totality of scientific evidence, including data from the Phase 3 ENSEMBLE study that demonstrated the vaccine was 85 percent effective in preventing severe disease across all regions studied, and showed protection agai...
Source: Johnson and Johnson - February 28, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Johnson & Johnson Single-Shot COVID-19 Vaccine Candidate Unanimously Recommended for Emergency Use Authorization by U.S. FDA Advisory Committee
NEW BRUNSWICK, N.J., February 26, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) unanimously voted to recommend Emergency Use Authorization (EUA) for the Company’s single-shot COVID-19 vaccine candidate for adults 18 and older, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson. The vote was based on a totality of scientific evidence provided by the Company, including efficacy and safety data from the Phase 3 ENSEMBLE trial. “We are e...
Source: Johnson and Johnson - February 26, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Scientists reveal details of antibodies that work against Zika virus
(Biophysical Society) The Zika outbreak of 2015 and 2016 is having lasting impacts on children whose mothers became infected with the virus while they were pregnant. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - February 25, 2021 Category: Infectious Diseases Source Type: news

Models to predict dengue, zika and yellow fever outbreaks are developed by researchers
(Funda ç ã o de Amparo à Pesquisa do Estado de S ã o Paulo) Scientists will monitor areas in which these diseases are endemic, such as S ã o Paulo, the Amazon, the Pantanal and Panama, to investigate the factors that trigger outbreaks (monkey being examined in Manaus á rea. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 23, 2021 Category: International Medicine & Public Health Source Type: news

Scientists use machine-learning approach to track disease-carrying mosquitoes
(Utah State University) A team of researchers from Utah State University, University of California, Davis and Yale University are using a machine-learning approach to map landscape connectivity of the species Aedes aegypti, the so-called Yellow Fever mosquito, which is a primary vector for transmission of viruses causing dengue fever, chikungunya and Zika. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - February 22, 2021 Category: Biology Source Type: news

Zika Vaccine Candidate Shows Promise in Phase 1 Trial Zika Vaccine Candidate Shows Promise in Phase 1 Trial
A Zika virus vaccine candidate prompted antibody responses in 80% of individuals who received two doses in a phase 1 study.Medscape Medical News (Source: Medscape Infectious Diseases Headlines)
Source: Medscape Infectious Diseases Headlines - February 19, 2021 Category: Infectious Diseases Tags: Infectious Diseases News Source Type: news

Johnson & Johnson Announces Submission to World Health Organization for Emergency Use Listing of Investigational Single-Shot Janssen COVID-19 Vaccine Candidate
NEW BRUNSWICK, N.J., February 19, 2021– Johnson & Johnson (NYSE: JNJ) (the Company) announced that Janssen-Cilag International N.V. has submitted for Emergency Use Listing (EUL) to the World Health Organization (WHO) for the investigational single-dose Janssen COVID-19 vaccine candidate. The data package delivered today includes interim efficacy and safety results from the Phase 3 ENSEMBLE clinical trial. The Company’s rolling submission of clinical data to WHO is now complete.“Our filing with the World Health Organization marks another important step in our effort to combat COVID-19 and also in our u...
Source: Johnson and Johnson - February 19, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Johnson & Johnson Announces Submission of European Conditional Marketing Authorisation Application to the EMA for its Investigational Single-Shot Janssen COVID-19 Vaccine Candidate
NEW BRUNSWICK, N.J., February 16, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced that Janssen-Cilag International N.V., has submitted a conditional Marketing Authorisation Application (cMAA) to the European Medicines Agency (EMA) seeking authorisation for its investigational single-dose Janssen COVID-19 vaccine candidate. The submission is based on topline efficacy and safety data from the Phase 3 ENSEMBLE clinical trial.“Throughout Europe, there remains an urgent need for additional COVID-19 vaccines, and today’s submission is a significant step forward in ensuring the European Un...
Source: Johnson and Johnson - February 16, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Drought restrictions had side benefit: Lowering risk of mosquito-borne disease
Shallow pools of water on lawns are ideal breeding grounds for the mosquitoes that transmit West Nile virus, the most common mosquito-borne disease in the United States.A new study by scientists from UCLA and three other universities found that reducing shallow pools of water where the insects lay their eggs is key to preventing the spread of the virus.The study, funded by a grant from the UC Office of the President and published in the journal Environmental Science and Technology, found that California ’s water-use restrictions during the statewide drought from 2012 to 2016 led to a decrease in the number of mosquit...
Source: UCLA Newsroom: Health Sciences - February 16, 2021 Category: Universities & Medical Training Source Type: news

Zika vaccine shows promise in early trials
A vaccine against Zika produced immunity to the mosquito-borne virus for up to a year in at least 80% of those who received it, a study published Monday by the Annals of Internal Medicine found. (Source: Health News - UPI.com)
Source: Health News - UPI.com - February 15, 2021 Category: Consumer Health News Source Type: news

Zika vaccine candidate shows promise in phase I trial
(American College of Physicians) The Zika virus candidate, Ad26.ZIKV.001, a replication-incompetent human adenovirus serotype 26 (ad26) vector showed promising safety and immunogenicity in a phase I clinical trial. Researchers say the vaccine warrants further development should the need reemerge. The findings are published in Annals of Internal Medicine. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - February 15, 2021 Category: Infectious Diseases Source Type: news

International Women's Day Panel on diversity in health evidence synthesis - 8 March 2021
International Women's Day is March 8th!  Join us as we discuss and highlight minority women and young investigators working in health science and evidence synthesis. Hear about their career paths, who has inspired them, and what advice they have for other women interested in or working in health evidence synthesis.  Learn about Cochrane’s role in evidence Synthesis and how anyone can get involved.Each year Cochrane hosts an event in the name of Anne Anderson, a pioneering woman in health evidence synthesis.   In the past it's been the'Ann Anderson Walk'at the Cochrane Colloquium to raise money for...
Source: Cochrane News and Events - February 9, 2021 Category: Information Technology Authors: Muriah Umoquit Source Type: news

International Women's Day Panel on diversity in health evidence synthesis
On International Women's Day 2021 we discussed and highlighted minority women and young investigators working in health science and evidence synthesis.  Watch the recording to hear about their career paths, who has inspired them, and what advice they have for other women interested in or working in health evidence synthesis.  Learn about Cochrane’s role in evidence Synthesis and how anyone can get involved.Each year Cochrane hosts an event in the name of Anne Anderson, a pioneering woman in health evidence synthesis.   In the past it's been the'Anne Anderson Walk'at the Cochrane Colloquium to rais...
Source: Cochrane News and Events - February 9, 2021 Category: Information Technology Authors: Muriah Umoquit Source Type: news

VIDEO: International Women's Day Panel on diversity in health evidence synthesis
On International Women's Day 2021 we discussed and highlighted minority women and young investigators working in health science and evidence synthesis.  Watch the recording to hear about their career paths, who has inspired them, and what advice they have for other women interested in or working in health evidence synthesis.  Learn about Cochrane’s role in evidence Synthesis and how anyone can get involved.Each year Cochrane hosts an event in the name of Anne Anderson, a pioneering woman in health evidence synthesis.   In the past it's been the'Anne Anderson Walk'at the Cochrane Colloquium to rais...
Source: Cochrane News and Events - February 9, 2021 Category: Information Technology Authors: Muriah Umoquit Source Type: news

Johnson & Johnson Announces Submission of Application to the U.S. FDA for Emergency Use Authorization of its Investigational Single-Shot Janssen COVID-19 Vaccine Candidate
NEW BRUNSWICK, N.J., February 4, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced that Janssen Biotech, Inc., has submitted an application to the U.S. Food and Drug Administration (FDA) requesting Emergency Use Authorization (EUA) for its investigational single-dose Janssen COVID-19 vaccine candidate. The Company’s EUA submission is based on topline efficacy and safety data from the Phase 3 ENSEMBLE clinical trial, demonstrating that the investigational single-dose vaccine met all primary and key secondary endpoints. The Company expects to have product available to ship immediately followi...
Source: Johnson and Johnson - February 4, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

In vitro study helps explain how Zika virus passes from mother to fetus during pregnancy
(University of South Florida (USF Health)) A preclinical study by a University of South Florida Health Morsani College of Medicine team has discovered a new mechanism for how Zika virus can pass from mothers to their children during pregnancy - a process known as vertical transmission. The researchers showed, for the first time, that specialized maternal cells lining the uterus (decidual cells) act as reservoirs for trimester-dependent transmission of the virus through the placenta. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 3, 2021 Category: International Medicine & Public Health Source Type: news

Johnson & Johnson Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial
NEW BRUNSWICK, N.J., January 29, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced topline efficacy and safety data from the Phase 3 ENSEMBLE clinical trial, demonstrating that the investigational single-dose COVID-19 vaccine in development at its Janssen Pharmaceutical Companies met all primary and key secondary endpoints. The topline safety and efficacy data are based on 43,783 participants accruing 468 symptomatic cases of COVID-19. The Phase 3 ENSEMBLE study is designed to evaluate the efficacy and safety of the Janssen COVID-19 vaccine candidate in protecting moderate to severe CO...
Source: Johnson and Johnson - January 29, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Johnson & Johnson Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial
NEW BRUNSWICK, N.J., January 29, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced topline efficacy and safety data from the Phase 3 ENSEMBLE clinical trial, demonstrating that the investigational single-dose COVID-19 vaccine in development at its Janssen Pharmaceutical Companies met all primary and key secondary endpoints. The topline safety and efficacy data are based on 43,783 participants accruing 468 symptomatic cases of COVID-19. The Phase 3 ENSEMBLE study is designed to evaluate the efficacy and safety of the Janssen COVID-19 vaccine candidate in protecting moderate to severe COVID-19, wit...
Source: Johnson and Johnson - January 29, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Study reveals cause of common Zika virus birth defect
(Cleveland Clinic) CLEVELAND - Cleveland Clinic researchers have described for the first time how Zika virus (ZIKV) causes one of the most common birth defects associated with prenatal infection, called brain calcification, according to new study findings published inNature Microbiology.The findings may reveal novel strategies to prevent prenatal ZIKV brain calcification and offer important insights into how calcifications form in other congenital infections. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - January 28, 2021 Category: Infectious Diseases Source Type: news

Genetically-modified mosquitoes key to stopping Zika virus spread
(University of Missouri-Columbia) In 2016, the World Health Organization called the Zika virus epidemic a " public health emergency of international concern " due to the virus causing birth defects for pregnant women in addition to neurological problems. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - January 26, 2021 Category: Biology Source Type: news

Dengue —an Epidemic Within a Pandemic in Peru
International Year of Volunteers: A volunteer ombudsman in Peru helps a local woman with her problem, 2001. Credit: UN PhotoBy Carmen ArroyoUNITED NATIONS, Jan 15 2021 (IPS) While the world is grappling with the third wave of the COVID-19 pandemic, Peru is still dealing with an epidemic that it has not been able to control—the mosquito-borne viral disease known as dengue. With almost 56,400 confirmed cases as of December, Peru is suffering the worst dengue epidemic since 2017, when the virus infected over 68,000 people. The illness, coupled with the novel coronavirus crisis, has left thousands of people exposed to m...
Source: IPS Inter Press Service - Health - January 15, 2021 Category: International Medicine & Public Health Authors: Carmen Arroyo Tags: Development & Aid Economy & Trade Featured Food Security and Nutrition Headlines Health Humanitarian Emergencies Labour Latin America & the Caribbean TerraViva United Nations Water & Sanitation Barilla Center for Food and Nutrition F Source Type: news

Johnson & Johnson ’s 1-Shot COVID-19 Vaccine Shows Promise in Early-Stage Trials
Johnson & Johnson’s experimental one-shot Covid-19 vaccine generated a long-lasting immune response in an early safety study, providing a glimpse at how it will perform in the real world as the company inches closer to approaching U.S. regulators for clearance. More than 90% of participants made immune proteins, called neutralizing antibodies, within 29 days after receiving the shot, according to the report, and all participants formed the antibodies within 57 days. The immune response lasted for the full 71 days of the trial. “Looking at the antibodies, there should be good hope and good reason that the va...
Source: TIME: Health - January 14, 2021 Category: Consumer Health News Authors: Riley Griffin / Bloomberg Tags: Uncategorized COVID-19 overnight wire Source Type: news

Johnson & Johnson COVID-19 Vaccine Candidate Interim Phase 1/2a Data Published in New England Journal of Medicine
January 13, 2021 -- Interim Phase 1/2a data were published today in the New England Journal of Medicine demonstrating that the Company’s single-dose investigational COVID-19 vaccine candidate (JNJ-78436735) – being developed by the Janssen Pharmaceutical Companies of Johnson & Johnson – provided an immune response that lasted for at least 71 days, the duration of time measured in this study in participants aged 18-55 years. A preview of part of these interim data was posted on medRxiv in September 2020.The Phase 1/2a interim analysis showed that the Company’s COVID-19 vaccine candidate induced a...
Source: Johnson and Johnson - January 13, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

New defense against dengue and emerging mosquito-borne viruses
(University of Queensland) New treatments to cut the global death rate from dengue, Zika and West Nile viruses could result from research led by The University of Queensland. Associate Professor Daniel Watterson from UQ's School of Chemistry and Molecular Biosciences said the team identified an antibody that improved survival rates in laboratory trials and reduced the presence of virus in the blood. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - January 7, 2021 Category: Biology Source Type: news

A broadly protective antibody that targets the flavivirus NS1 protein
There are no approved flaviviral therapies and the development of vaccines against flaviruses has the potential of being undermined by antibody-dependent enhancement (ADE). The flavivirus nonstructural protein 1 (NS1) is a promising vaccine antigen with low ADE risk but has yet to be explored as a broad-spectrum therapeutic antibody target. Here, we provide the structural basis of NS1 antibody cross-reactivity through cocrystallization of the antibody 1G5.3 with NS1 proteins from dengue and Zika viruses. The 1G5.3 antibody blocks multi-flavivirus NS1-mediated cell permeability in disease-relevant cell lines, and therapeuti...
Source: ScienceNOW - January 7, 2021 Category: Science Authors: Modhiran, N., Song, H., Liu, L., Bletchly, C., Brillault, L., Amarilla, A. A., Xu, X., Qi, J., Chai, Y., Cheung, S. T. M., Traves, R., Setoh, Y. X., Bibby, S., Scott, C. A. P., Freney, M. E., Newton, N. D., Khromykh, A. A., Chappell, K. J., Muller, D. A., Tags: Biochemistry, Microbiology reports Source Type: news

Structural basis for antibody inhibition of flavivirus NS1-triggered endothelial dysfunction
Medically important flaviviruses cause diverse disease pathologies and collectively are responsible for a major global disease burden. A contributing factor to pathogenesis is secreted flavivirus nonstructural protein 1 (NS1). Despite demonstrated protection by NS1-specific antibodies against lethal flavivirus challenge, the structural and mechanistic basis remains unknown. Here, we present three crystal structures of full-length dengue virus NS1 complexed with a flavivirus–cross-reactive, NS1-specific monoclonal antibody, 2B7, at resolutions between 2.89 and 3.96 angstroms. These structures reveal a protective mecha...
Source: ScienceNOW - January 7, 2021 Category: Science Authors: Biering, S. B., Akey, D. L., Wong, M. P., Brown, W. C., Lo, N. T. N., Puerta-Guardo, H., Tramontini Gomes de Sousa, F., Wang, C., Konwerski, J. R., Espinosa, D. A., Bockhaus, N. J., Glasner, D. R., Li, J., Blanc, S. F., Juan, E. Y., Elledge, S. J., Mina, Tags: Biochemistry, Microbiology reports Source Type: news

From allergies to Zika — ABCs of environmental health
A brand new edition of the popular “Environment and Health A to Z” booklet includes eye-catching illustrations and easy-to-understand text. (read more) (Source: Environmental Factor - NIEHS Newsletter)
Source: Environmental Factor - NIEHS Newsletter - January 6, 2021 Category: Environmental Health Source Type: news

NIH launches large study of pregnant women and Zika
NIEHS is joining a National Institutes of Health study of risks that Zika infection poses to pregnant women, their fetuses, and infants. (read more) (Source: Environmental Factor - NIEHS Newsletter)
Source: Environmental Factor - NIEHS Newsletter - January 6, 2021 Category: Environmental Health Source Type: news

Natural products with potential efficacy against lethal viruses
(University of California - San Diego) Researchers describe the biology of three families of RNA viruses including Coronavirus, Ebola, and Zika and the natural products that have been shown to have capabilities to inhibit them. The review provides a guide that could accelerate drug discovery in response to future epidemics. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - January 5, 2021 Category: Infectious Diseases Source Type: news

Human Fetuses Can Contract SARS-CoV-2, but It's Rare
Compared with Zika and cytomegalovirus, the virus that causes COVID-19 appears to have a harder time penetrating the placenta and moving to a woman's unborn baby. (Source: The Scientist)
Source: The Scientist - January 1, 2021 Category: Science Tags: Features Magazine Issue Source Type: news

Could Invasive Mosquito Populations Pose Risk For Zika Virus Outbreaks?
A new study finds that despite the low-risk that Asian tiger mosquitoes pose for the Zika virus, active surveillance and eradication programs should be implemented in territories occupied by them to prevent major outbreaks. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - December 31, 2020 Category: Pharmaceuticals Authors: Anuradha Varanasi, Contributor Tags: Healthcare /healthcare Innovation /innovation Source Type: news

Asian tiger mosquito poses low risk for Zika virus outbreaks
(PLOS) The Asian tiger mosquito does not pose a major risk for Zika virus epidemics, according to a study published December 31 in the open-access journalPLOS Pathogens by Albin Fontaine of the Institut de Recherche Biom é dicale des Arm é es, and colleagues. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - December 31, 2020 Category: Biology Source Type: news

Zika virus affects eye development before but not after birth
(University of California - Davis) A new study from UC Davis finds that Zika infection during the first trimester of pregnancy can impact fetal retinal development and cause congenital ocular anomalies. The virus does not appear to affect ocular growth postnatally. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 18, 2020 Category: International Medicine & Public Health Source Type: news

NIH grant funds development of novel biosensor technology for diagnosing viral infections
(University of California - Santa Cruz) For over ten years, Ali Yanik has been working to develop novel biosensor technology to provide rapid, low-cost testing for disease diagnostics and precision medicine. Now, with a five-year, $3.7 million grant from the National Institutes of Health, he and his collaborators are poised to complete the development and validation of a prototype and begin testing it in the field for detection of dengue fever, yellow fever, and Zika virus infections. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - December 16, 2020 Category: Infectious Diseases Source Type: news

New viral detection technique uses smartphone camera to diagnose various infections
(American Association for the Advancement of Science) Scientists have developed a novel smartphone-based technique to diagnose viral infections that uses a deep learning algorithm to identify viruses in metal nanoparticle-labeled samples, enabling rapid virus detection without the need for skilled laboratory workers and expensive equipment. The system correctly identified clinically relevant concentrations of Zika, hepatitis B (HBV), or hepatitis C (HCV) in 134 patient samples with 98.97% sensitivity. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - December 16, 2020 Category: Infectious Diseases Source Type: news

$2 million NIH grant to develop Zika virus vaccine
(Virginia Tech) " This grant focuses on a new strategy that we developed to produce safe and effective flavivirus vaccines. It aims to prevent the emergence of these viruses -- in this case Zika virus -- in humans, " said Jonathan Auguste (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - December 9, 2020 Category: Infectious Diseases Source Type: news